BarrySSkikneMD

Hematology • Kansas City, KS

Physician

Join to view full profile

Dr. Skikne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Skikne's full profile

Already have an account?

Office
3901 Rainbow Blvd
Kansas City, KS 66160
Phone+1 913-588-6000

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1977 - 1979
University of the WitwatersrandClass of 1969

Certifications & Licensure

KS State Medical License 1978 - 2025

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia Start of enrollment: 2007 Sep 11
Completed
Phase 1
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma Start of enrollment: 2008 Aug 12
Completed
Phase 1
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine Start of enrollment: 2012 Feb 07
Completed
Phase 1
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2013 Apr 26
COMPLETED
PHASE3
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission Start of enrollment: 2013 Apr 24
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
Courtney D DiNardo, Rebecca Olin, Eunice S Wang, Barry Skikne, Joseph Rosenthal
Cancer Medicine. 2024-07-01
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the...
Andrew H Wei, Gail J Roboz, Herve Dombret, Hartmut Dohner, Andre C Schuh
Haematologica. 2023-10-01
2 citations
Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.
Allison Gaudy, Eric Laille, Rochelle Bailey, Simon Zhou, Barry Skikne
Clinical Pharmacology and Therapeutics. 2023-10-01

Abstracts/Posters

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
Barry S. Skikne, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing
Barry S. Skikne, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Remembering James Cook, Oncology Researchers Receive 2020 NIH Director’s New Innovator Awards, and MoreFebruary 1st, 2021